Abstract 2124
Background
To explore the differences of MRI scan between pituitary adenomas and craniopharyngioma from MR image features to 3D based texture features.
Methods
A total number of 131 patients were introduced into this study (pituitary Adenomas =68; craniopharyngioma=63) with pre-surgery MRI image. Qualitative MR features and MRI texture features of lesion were evaluated using chi-square tests, Fisher exact test or Mann-Whitney U test. Multivariate logistic regression analyses were performed to access their ability as independent predictors. Accuracy measures were calculated substantially for the significant features.
Results
Five MRI features were suggested to be significantly different between pituitary adenomas and craniopharyngioma and one of them, cystic alteration could be considered as independent practical predictors. Three texture features from contrast enhanced images (Histo-Skewness, GLCM-Contrast and GLCM-Energy), two texture features from T2WI (Histo-Skewness and GLCM-Contrast) were found to be significantly related to discrimination between two types of diseases. Two texture features (Histo-Skewness and GLCM-Contrast) were found significantly to be in relation with cystic alteration.
Conclusions
Both of MRI image features and texture features, could make significant discrimination between pituitary adenoma and craniopharyngioma and represent practical diagnostic value; in addition, two type features associate with each other.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuelei Ma.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3780 - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Presenter: Salah-Eddin Al-Batran
Session: Poster Display session 2
Resources:
Abstract
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor
Presenter: Zhao Sun
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract